Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Breast 1

Conditions

Breast Neoplasms 10Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Meningeal Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Metastatic 1Brain Neoplasms 1

Interventions

Paclitaxel 26pembrolizumab 24Docetaxel 20Capecitabine 19Fulvestrant 17Trastuzumab 16Anastrozole 15Cyclophosphamide 14Lapatinib 13Letrozole 11Carboplatin 11Radiotherapy 10Doxorubicin 10palbociclib 9Therapeutics 9Nivolumab 9Exercise 9Gemcitabine 8Cisplatin 8Blood Specimen Collection 8Tamoxifen 7Bevacizumab 7liposomal doxorubicin 6exemestane 6abemaciclib 6Vinorelbine 6Standard of Care 6Fluorouracil 6atezolizumab 5Surveys and Questionnaires 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × patritumab deruxtecan × Breast × Clear all
NCT02980341 2024-10-30

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Daiichi Sankyo

Phase 1/2 Completed
182 enrolled 37 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡